The FDA approved Revolution Medicines’ daraxonrasib, marketed as Rasonque, for advanced pancreatic ductal adenocarcinoma, following clinical evidence that supports a survival benefit over standard chemotherapy in the studied setting. The approval specifically covers previously treated advanced patients. The decision follows Revolution’s practice-changing trial readout earlier this year, with median overall survival reported at 13.2 months on daraxonrasib versus 6.7 months with chemotherapy. The approval positions Revolution Medicines’ Rasonque as the first FDA-authorized RAS-targeting option in this disease context, setting up rapid uptake pressure across oncology practices and payers.